Trials / Completed
CompletedNCT07450170
A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
Treatment Patterns of Omalizumab in Chronic Urticaria Patients in China: A Retrospective Real-World Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,485 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to characterize the real-world treatment patterns of omalizumab among adult patients with chronic urticaria in China using data from a regional electronic healthcare (rEHR) database. This included assessing the frequency and proportion of prescriptions across different dosages of omalizumab in real-world clinical practice.
Conditions
Timeline
- Start date
- 2026-03-10
- Primary completion
- 2026-03-23
- Completion
- 2026-03-23
- First posted
- 2026-03-04
- Last updated
- 2026-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07450170. Inclusion in this directory is not an endorsement.